Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Sonoma Pharmaceuticals ( (SNOA) ) is now available.
On August 27, 2025, Sonoma Pharmaceuticals held its annual stockholders meeting where several key proposals were voted on. Dr. Jay Birnbaum was elected as a Class II director, executive compensation for the year ended March 31, 2025, was approved, Frazier & Deeter, LLC was ratified as the independent registered public accounting firm for the fiscal year ending March 31, 2026, and a proposal to adjourn the meeting for further proxy solicitation was also approved.
The most recent analyst rating on (SNOA) stock is a Hold with a $5.50 price target. To see the full list of analyst forecasts on Sonoma Pharmaceuticals stock, see the SNOA Stock Forecast page.
Spark’s Take on SNOA Stock
According to Spark, TipRanks’ AI Analyst, SNOA is a Neutral.
Sonoma Pharmaceuticals’ stock score is primarily influenced by strong technical indicators, with the stock trading above key moving averages. However, financial performance concerns, including profitability and cash flow challenges, and a negative P/E ratio weigh heavily on the score. The absence of earnings call data and corporate events means these factors did not influence the score.
To see Spark’s full report on SNOA stock, click here.
More about Sonoma Pharmaceuticals
Average Trading Volume: 1,284,848
Technical Sentiment Signal: Buy
Current Market Cap: $7.49M
See more data about SNOA stock on TipRanks’ Stock Analysis page.